Lipopeptide

$3.8 Billion MRSA Drugs Markets by Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region - Global Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mars 29, 2024
Health, Pharmaceutical, MRSA, Urbanization, Growth, Prevalence, Fungal infection, Pharmacy, Research, Bacteria, Genetically modified bacteria, Tetracycline, Infection, Skin, Lipopeptide, Market, Administration, CA-MRSA, Pharmaceutical industry

The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs.
  • The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type.
  • The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration.

Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting

Retrieved on: 
Lundi, octobre 17, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, LinkedIn, Doctor of Pharmacy, CDC, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Office of Inspector General, U.S. Department of Health and Human Services, PD, Society of Infectious Diseases Pharmacists, Infection, Biopharma LLC, Pharmacist, Twitter, Partnership, WHO, BARDA, World, Acinetobacter, Acinetobacter baumannii, Aivo Orav, Society, Pseudomonas aeruginosa, Health, PIDS, OTA, Infectious Diseases Society of America, Beta-lactam, World Health Organization, Lipopeptide, IDSA, Pharmacokinetics, Drug of last resort, ID, ESBL, Pharmaceutical industry, Hospital, Tolerability, Pseudomonas, FIDSA, Safety

Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.

Key Points: 
  • Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.
  • The presentations will describe progress on three Qpex investigational products that the recent WHO pipeline analysis identified as addressing drug-resistant pathogens for which there is a critical need for new drugs.
  • QPX9003: a next-generation, IV-administered synthetic lipopeptide with an enhanced therapeutic profile designed to focus on highly drug-resistant infections caused by Pseudomonas and Acinetobacter.
  • The company also has a partnership with Brii Biosciences for the development and commercialization of three of its products in greater China.

Global Biosurfactants Market Report 2022: Growing Personal Care Application to Drive Sector - ResearchAndMarkets.com

Retrieved on: 
Mardi, septembre 20, 2022
Manufacturing, Home Goods, Other Manufacturing, Other Retail, Retail, Health, Carbon, Safety, Textile, Rhamnose, Detergent, NAFTA, Growth, Agriculture, North American Free Trade Agreement, Rhamnolipid, Environment, USD, Pseudomonas, Biosurfactant, Soap, Water, Cosmetics, Awareness, Glycolipid, Soil, CAGR, Lithium, Lipopeptide

The "Global Biosurfactants Market by Type (Glycolipids, Lipopeptides), Application (Detergent, Personal care, Food processing, Agricultural chemicals) and Region (North America, Europe, Asia Pacific, Rest of the World) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosurfactants Market by Type (Glycolipids, Lipopeptides), Application (Detergent, Personal care, Food processing, Agricultural chemicals) and Region (North America, Europe, Asia Pacific, Rest of the World) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biosurfactants market will grow to USD 1.9 Billion by 2027, at a CAGR of 11.2% from USD 1.2 Billion in 2022.
  • The global surfactants market is primarily dominated by synthetic surfactants derived from oleochemical or petrochemical sources.
  • They are the major components of products we use on a daily basis, such as detergents, cosmetics, agricultural products, construction products, textiles, and food & beverages.

Global Peptide Therapeutics Market & Clinical Trials Insight Report 2022: Market Set to Surpass US$ 75 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mai 6, 2022
Health, Pharmaceutical, Dermatology, Peptide therapeutics, US, Gastroenterology, Company, Bone, Peptide, Endocrinology, Contract, Prevalence, Indication, Insulin, Attention, Degenerative disease, Cancer, Diabetes, Therapy, Industry, Conditional sentence, Vaccine, Glucagon-like peptide-2, Genentech, Organic acid, Research, Lists of diseases, Growth, Sexual dysfunction, Fine chemical, Neuropeptide, Glycopeptide, Natriuresis, Dipeptide, Depsipeptide, Oligopeptide, Lipopeptide

The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests a promising future of peptide therapeutics in the forthcoming years.
  • Keeping the clinical pipeline into consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028.
  • Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report highlights:
    Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
    Peptide Therapeutics in Clinical trials: > 800 Drugs
    Peptide Therapeutics Commercially Available In Market: > 200 Drugs
    Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides

Qpex Biopharma Announces Presentation of Clinical Data for Ultra-Broad Spectrum β-lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003 at ECCMID 2022 Meeting

Retrieved on: 
Jeudi, avril 21, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Online, Adult, Acinetobacter, Office of Inspector General, U.S. Department of Health and Human Services, OTA, Human services, Office of the Assistant Secretary for Preparedness and Response, CDC, Twitter, WHO, Pseudomonas aeruginosa, CET, Nature Communications, European, Infection, Date-time group, Lipopeptide, Biomedical Advanced Research and Development Authority, Patient, ESBL, World Health Organization, Drug of last resort, LinkedIn, Pharmacokinetics, World, Development, Congress, Health, Doctor of Pharmacy, Assistant, BARDA, Partnership, Pharmaceutical industry, Pseudomonas, Safety, Tolerability

Qpex Biopharma, Inc. (Qpex), a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced the company will present new clinical data for their -lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held on April 23-26, 2022.

Key Points: 
  • Qpex Biopharma, Inc. (Qpex), a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced the company will present new clinical data for their -lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held on April 23-26, 2022.
  • The ECCMID meeting will be held as a hybrid event both online, as well as onsite in Lisbon, Portugal.
  • QPX9003: a next-generation, IV-administered synthetic lipopeptide with an enhanced therapeutic profile designed to focus on highly drug-resistant infections caused by Pseudomonas and Acinetobacter.
  • Advancing a robust portfolio of best-in-class, clinical-stage products, the companys lead program are based on xeruborbactam, a novel ultra-broad-spectrum beta-lactamase inhibitor discovered by Qpex scientists.

Global Antibiotics Markets Report 2021-2026: Analysis by Drug Class - Beta-Lactams, Cephalosporins, Lipopeptide, Others - ResearchAndMarkets.com

Retrieved on: 
Mardi, janvier 4, 2022
Health, Pharmaceutical, Country, Beta-lactam, Value, Cephalosporin, DNA synthesis, Penicillin, Lipopeptide, Aquaculture, Pharmaceutical industry, Fine chemical

4.1 Global Antibiotics Market Size, By Value, Year 2016-2026

Key Points: 
  • 4.1 Global Antibiotics Market Size, By Value, Year 2016-2026
    5.
  • Global Antibiotics Market Segmentation - By Drug Class, By Mechanism
    5.1 Competitive Scenario of Global Antibiotics Market: By Drug Class
    5.2 Competitive Scenario of Global Antibiotics Market: By Mechanism
    6.1 Competitive Scenario of Global Antibiotics Market: By Region
    7.1 North America Antibiotics Market: Size and Forecast (2016-2026), By Value
    7.3 Market Segmentation by Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
    7.4 Market Segmentation by Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
    7.5 North America Antibiotics Market: Country Analysis
    7.6 Market Opportunity Chart of North America Antibiotics Market - By Country, By Value, 2026
    7.7 Competitive Scenario of North America Antibiotics Market: By Country
    11.1 Market Attractiveness Chart of Global Antibiotics Market - By Drug Class, 2026
    11.2 Market Attractiveness Chart of Global Antibiotics Market - By Mechanism, 2026
    11.3 Market Attractiveness Chart of Global Antibiotics Market - By Region, 2026
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005583/en/

Immuno-Uro-Prostanorm Bolsters Men Below the Belt

Retrieved on: 
Jeudi, août 26, 2021
Population, Ageing, Lipopeptide, Blood, Lipopolysaccharide, Immune system, Infection, Association, Prostate, Research, Urinary tract infection, Man, Time-invariant system, Zinc, BPH, Stone, Solution, D3, Urine, Medical imaging, Dietary supplement

The dietary supplement is designed for men over the age of 40 and is meant to be taken for a minimum of 3 months in order to take effect.

Key Points: 
  • The dietary supplement is designed for men over the age of 40 and is meant to be taken for a minimum of 3 months in order to take effect.
  • This is especially true for men dealing with benign prostatic hyperplasia (BPH) a condition that is a leading cause of an enlarged prostate.
  • BPH alone is a concern for 50% of men between 51 and 60 years old , and the number only goes up from there.
  • The company is most well known for its unique, patented ingredient, which it refers to as an immuno-modulator.